Cyclophosphamide disposition in an anephric child

Pediatric Blood and Cancer

Volumn 46, Issue 1, 2006, Pages 99-104

  McCune, Jeannine S ^a,b   Adams, Denise ^c   Homans, Alan C ^d   Guillot, Ann ^d   Iacono, Lisa ^e   Stewart, Clinton F ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c Cincinnati Childrens Hosp Med Ctr   (United States)

^d FLETCHER ALLEN HEALTH CARE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anephric; Cyclophosphamide; Pharmacokinetic; Renal

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CARBOXYETHYLPHOSPHORAMIDE MUSTARD; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; LABETALOL; LISINOPRIL; LORAZEPAM; MESNA; ONDANSETRON; PHOSPHORAMIDE MUSTARD; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY AGENESIS; KIDNEY FAILURE; MALE; NEPHROBLASTOMA; NEUTROPENIA; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CYCLOPHOSPHAMIDE; HUMANS; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; RENAL DIALYSIS; WILMS TUMOR;

EID: 28844507982     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20558     Document Type: Article

References (41)

1. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
2. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
3. Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated Cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-255.
4. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin lymphoma. J Clin Oncol 2003;21:3041-3050.
5. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
6. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-1494.
7. Kaijser GP, Beijnen JH. Oxazaphosphorines: Cyclophosphamide and Ifosfamide. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore: Williams & Wilkins; 1998. p 229-258.
8. McCune JS, Slattery JT. Pharmacological Considerations of Primary Alkylators. In: Andersson B, Murray D, editors. Clinically relevant resistance in cancer chemotherapy. Boston: Kluwer Academic Publishers; 2002. p 323-337.
9. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
10. Bagley CM, Jr., Bostick FW, DeVita VT, Jr. Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226-233.
11. Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer 1976;37:665-670.
12. Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation [published erratum appears in Cancer Res 1995 Apr 1;55(7):1600]. Cancer Res 1995;55:810-816.
13. Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998;64:289-301.
14. Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-4235
15. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-2469.
16. Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992;30:207-211.
17. Estlin EJ, Veal GJ. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 2003;29:253-273.
18. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
19. Yule SM, Price L, McMahon AD, et al. Cyclophosphamide metabolism in children with non-Hodgkin lymphoma. Clin Cancer Res 2004;10:455-460.
20. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975;36:409-414.
21. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981;19:443-451.
22. Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979;3:253-259.
23. Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002;61:1495-1501.
24. Bischoff ME, Blau W, Wagner T, et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant 1998;22:591-593.
25. Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant 1999;23:839-842.
26. Bending MR, Finch RE. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:1145-1146.
27. Wang LH, Lee CS, Majeske BL, et al. Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 1981;29:365-372.
28. Wagner T, Heydrich D, Bartels H, et al. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites]. Arzneimittelforschung 1980;30:1588-1592. German.
29. Chan KK, Hong PS, Tutsch K, et al. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994;54:6421-6429.
30. Anderson LW, Chen TL, Colvin OM, et al. Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide kinetics in patients receiving high-dose Cyclophosphamide chemotherapy. Clin Cancer Res 1996;2:1481-1487.
31. Saylors RL 3rd, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:945-952.
32. Kalhorn TF, Ren S, Howald WN, et al. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1999;732:287-298.
33. Iacone L, Adams D, Homans AC, et al. Topotecan disposition in an anepric child. J Pediatr Hematol Oncol 2004;26:596-600.
34. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
35. Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497-503.
36. Cagnoni PJ, Matthes S, Day TC, et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1-4.
37. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res 1995;55:803-809.
38. Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 2001;47:222-228.
39. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-366.
40. Milsted RA, Jarman M. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:820-821.
41. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996;41:13-19.